BSEResult3 Nov 2026 · 3 Nov 2026, 07:23 pm
Unaudited Financial Results for the Quarter and half year ended as on September 30, 2026
Evonile Pharma Ltd · 500672
✦ AI SummaryResults
Evonile Pharma Ltd has submitted its unaudited financial results for the quarter and half year ended September 30, 2026, with total financial indebtedness of Rs. 800 crore, including short-term and long-term debt. The company has disclosed related party transactions with its subsidiaries and has not reported any defaults on loans or debt securities.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Evonile Pharma Ltd - 500672 - Unaudited Financial Results For The Quarter And Half Year Ended As On September 30, 2026.
Attachments (1)
📄pdf
Download →
a57b4a67-e392-47fb-a2be-568e17eb6fb3.pdf
View document text
Evonile Pharma Limited
(formerly known as Novartis India Limited)
November 03, 2026
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 500672
Sub.: Integrated Filing (Financial) for the Quarter and half year ended September 30, 2026.
Dear Sir/ Madam,
Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-
2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No.
NSE/CML/2025/02 dated January 2, 2025, we hereby submit the Unaudited Financial Statements for
the quarter and half year ended September 30, 2026, together with the Limited Review Report
thereon (Annexures I and II), along with the other disclosures forming part of the Integrated Filing
(Financial) for the quarter and half year ended September 30, 2026.
This is for your information and records.
Thanking You,
For Evonile Pharma Limited
(Formerly known as Novartis India Limited)
Chandni Maru
Company Secretary & Compliance Officer
A60291
Encl: as above
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com
Evonile Pharma Limited
(formerly known as Novartis India Limited)
Integrated Filing (Financial) for the quarter and half year ended September 30, 2026.
B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue,
Qualified Institutions Placement etc.: Not Applicable
C. Disclosure of Outstanding Default on Loans and Debt Securities: - Not Applicable
Sr Particulars Amount
No. (INR)
1. Loans / revolving facilities like cash credit from banks
/ financial institutions
A. Total amount outstanding as on date 800
B. Of the total amount outstanding, amount of default as Nil
on date
2. Unlisted debt securities i.e. NCDs and NCRPS -
A. Total amount outstanding as on date -
B. Of the total amount outstanding, amount of default as -
on date
3. Total financial indebtedness of the listed entity including 800
short-term and long-term debt
D. Disclosure of Related Party Transactions (Applicable only for Half Yearly Filings (i.e. 02nd and
04th Quarter): Annexure-III
E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted
Along with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable
Only for Annual Filing i.e. 4th Quarter): Not Applicable
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com
Evonile Pharma Limited
(formerly known as Novartis India Limited)
Annexure III
Value
of the
related Value Value
party Value of of of
transac transacti transac transa
Type of tion as on tion ction
In case amount
related approv during during during
are due to either
Details of the counterparty party ed by the the the
party as a result of
transacti the reporting reportin reporti
the transaction
on audit period g ng
commit QTD period period
tee/ Sep'26 YTD YTD
Board Sep'26 Jun'26
FY26
Relationshi
p of the
Openi
counterpar
QTD YTD YTD ng Closing
Name Name ty with the
Sep'26 Sep'26 Jun'26 balan balance
listed
entity or its
subsidiary
Novartis AG - Subsidiary Royalty -
1 Upto 29th July 48.76 1.43 9.42 7.99 10.92 -8.48
2026
Novartis Subsidiary NBS -2.23
Healthcare services 30.00 1.97 7.90 5.92 -2.23
2 Private Limited
- Upto 29th
July 2026
Novartis Subsidiary Business
Healthcare support 66.00 20.06 34.67 14.61 -3.05 -25.51
3 Private Limited services
Evonile
- Upto 29th availed
Pharma
July 2026
Limited
Novartis Subsidiary Promotio
(Formely
Healthcare nal and 12.10 0.74 2.86 2.13 0.81 0.79
known as
4 Private Limited marketin
Novartis
- Upto 29th g
India
July 2026 services
Lim ited)
Novartis Subsidiary ESO
Healthcare services 41.00 0.42 6.97 6.55 3.05 0.45
5 Private Limited provided
- Upto 29th
July 2026
Subsidiary Employe
Novartis
e 5.00 0.35 0.35 - - -0.24
Healthcare
balances
6 Private Limited
transferr
- Upto 29th
ed –
July 2026
payable
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com
Evonile Pharma Limited
(formerly known as Novartis India Limited)
Subsidiary Employe 0.00
Novartis e 5.00 2.85 2.85 - -
Healthcare balances
7 Private Limited transferr
- Upto 29th ed –
July 2026 receivabl
Novartis India Subsidiary Provident
Limited fund 120.00 0.47 2.18 1.70 - -
Employees' contributi
Provident Fund on
Novartis India Subsidiary Superann
Limited uation 3.00 - - - - -
Superannuatio contributi
n Fund on
Subsidiary Gratuity 0.00
Novartis India
fund 23.00 - - - -
10 Limited
contributi
Gratuity fund
Novartis Subsidiary Purchase -
Pharma AG - of stock 3,000.0 97.80 526.57 428.77 293.3 -97.80
Upto 29th July in trade 0 2
2026
Novartis- Subsidiary ESOP /
Mitarbeiterbet ESPP 10.00 - 0.06 0.06 -3.50 -
eiligungsstiftu
ng (MBS) -
Upto 29th July
2026
To 3363.86 126.09 593.83 467.74
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com